Cybin Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cybin Inc (CYBN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cybin Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 159M vs 82M combined for tracked competitors (66.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-23.3%) for its tracked peer group.
- Growth: Cybin Inc generated 123.7% revenue growth year over year in Q4 2025, vs 94.2% for its tracked competitors combined.
- Profitability: Its -54.5% net margin compares with -1,030.3% for the peer group.
- Peer revenue share: Cybin Inc accounted for 91.0% of combined revenue among its tracked peer group, up from 89.8% a year earlier.
- Peer differentiation: Revenue per employee of $5.30M compares with $0.17M for the peer group (31.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CYBN Sales vs. its Competitors, Q4 2025
Cybin Inc reported revenue growth of 123.74 % year on year in Q4 2025, above its competitors' combined revenue growth of 94.23 %.
With a net margin of -54.45 %, Cybin Inc achieved higher profitability than its competitors (-1,030.34 %).
Cybin Inc generated 91.00 % of the combined sales of its peer group, up from 89.77 % a year earlier.
Cybin Inc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cybin Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cybin Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cybin Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 123.7% for Cybin Inc. Cybin Inc's share of combined industry revenue moved from 0.01% to 0.02%, a gain of 0.01 percentage points.
Cybin Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cybin Inc | - | - | - | - |
| Competitors combined (17) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CYBN Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Alto Neuroscience Inc | 282.9% | Outperformed |
| 2 | Compass Pathways Plc | 282.9% | Outperformed |
| 3 | Promis Neurosciences inc | 282.9% | Outperformed |
| 4 | Nrx Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Bright Minds Biosciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cybin Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cybin Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cybin Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cybin Inc | 167.44 | 159.15 |
| Ataibeckley Inc | 2,651.54 | 4.47 |
| Compass Pathways Plc | 1,786.58 | - |
| Alto Neuroscience Inc | 1,141.39 | - |
| Sage Therapeutics Inc | 543.46 | 70.41 |
| Bright Minds Biosciences Inc | 355.32 | - |
| SUBTOTAL | 6,939.86 | 326.43 |
Sign in to see all competitors of Cybin Inc .
Sources: Cybin Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cybin Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cybin Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cybin Inc | 167 | 5,304,933 | -2,888,765 |
| Ataibeckley Inc | 2,652 | 22,144 | -3,308,347 |
| Compass Pathways Plc | 1,787 | - | -2,526,840 |
| Alto Neuroscience Inc | 1,141 | - | -1,238,794 |
| Sage Therapeutics Inc | 543 | 199,462 | -853,244 |
| Bright Minds Biosciences Inc | 355 | - | -164,345 |
| PEERS TOTAL | 6,772 | 169,311 | -1,740,974 |
Cybin Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Cybin Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cybin Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Cybin Inc | 167 | 0.00 % |
Market cap and industry share for the rest of Cybin Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-01-02.
Cybin Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Cybin Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Cybin Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Cybin Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of tracked competitors (40.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-23.3% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cybin Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cybin Inc | 6.30 | 7.75 | - |
| Ataibeckley Inc | 3.50 | 9.64 | 0.03 |
| Compass Pathways Plc | 1.28 | 1.47 | 0.48 |
| Alto Neuroscience Inc | 16.39 | 16.63 | 0.11 |
| Sage Therapeutics Inc | 1.30 | 8.83 | - |
| Bright Minds Biosciences Inc | 35.50 | 36.10 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cybin Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cybin Inc | Q1 2025 | +123.7 % | - |
| Ataibeckley Inc | Q2 2026 | +137.0 % | - |
| Compass Pathways Plc | Q2 2026 | - | - |
| Alto Neuroscience Inc | Q2 2026 | - | - |
| Sage Therapeutics Inc | Q2 2025 | +265.8 % | - |
| Bright Minds Biosciences Inc | Q3 2025 | - | - |
| PEERS TOTAL | +73.4 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cybin Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cybin Inc | Q1 2025 | - | - |
| Ataibeckley Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q2 2026 | - | - |
| Alto Neuroscience Inc | Q2 2026 | - | - |
| Sage Therapeutics Inc | Q2 2025 | - | - |
| Bright Minds Biosciences Inc | Q3 2025 | - | - |
Cybin Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cybin Inc | - | - | - |
| Ataibeckley Inc | - | - | - |
| Compass Pathways Plc | - | - | - |
| Alto Neuroscience Inc | - | - | - |
| Sage Therapeutics Inc | - | - | - |
| Bright Minds Biosciences Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cybin Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cybin Inc | - | 1.05 |
| Ataibeckley Inc | - | 592.79 |
| Compass Pathways Plc | - | - |
| Alto Neuroscience Inc | - | - |
| Sage Therapeutics Inc | - | 7.72 |
| Bright Minds Biosciences Inc | - | - |
| PEERS AVERAGE | - | 21.26 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.